And itâ€™s not just Shkreli and Turing similar instances of extreme   just within the last year, have been seen in the pharma companies Mylan and Valeant.   To be sure, compared to the industry as a whole, those smaller companies stand as obnoxious outliers.   However, according to an August 2016 article in the Journal of the American Medical Association, the problem of high prices is, indeed, systemic:  Per capita prescription drug spending in the United States exceeds that in all other countries, largely driven by   drug prices that have been increasing in recent years at rates far beyond the consumer price index.   In 2013, per capita spending on prescription drugs was $858 compared with an average of $400 for 19 other industrialized nations. 